LGND Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -72.62% compared to Ligand Pharmaceuticals's net margin of 15.24%. Ligand Pharmaceuticals's return on equity of -0.51% beat Johnson & Johnson's return on equity of 19.98%.

Ligand Pharmaceuticals has a consensus price target of $143.57, signalling upside risk potential of 37.69%. On the other hand Johnson & Johnson has an analysts' consensus of $169.87 which suggests that it could grow by 11.96%. Given that Ligand Pharmaceuticals has higher upside potential than Johnson & Johnson, analysts believe Ligand Pharmaceuticals is more attractive than Johnson & Johnson.

Ligand Pharmaceuticals has a beta of 1.099, which suggesting that the stock is 9.858% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

Ligand Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.27% to investors and pays a quarterly dividend of $1.24 per share. Ligand Pharmaceuticals pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ligand Pharmaceuticals quarterly revenues are $42.8M, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Ligand Pharmaceuticals's net income of -$31.1M is lower than Johnson & Johnson's net income of $3.4B. Notably, Ligand Pharmaceuticals's price-to-earnings ratio is 46.13x while Johnson & Johnson's PE ratio is 26.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals is 11.47x versus 4.15x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

MetaVia has a net margin of -72.62% compared to Ligand Pharmaceuticals's net margin of --. Ligand Pharmaceuticals's return on equity of -0.51% beat MetaVia's return on equity of --.

Ligand Pharmaceuticals has a consensus price target of $143.57, signalling upside risk potential of 37.69%. On the other hand MetaVia has an analysts' consensus of $15.00 which suggests that it could grow by 934.48%. Given that MetaVia has higher upside potential than Ligand Pharmaceuticals, analysts believe MetaVia is more attractive than Ligand Pharmaceuticals.

Ligand Pharmaceuticals has a beta of 1.099, which suggesting that the stock is 9.858% more volatile than S&P 500. In comparison MetaVia has a beta of 0.217, suggesting its less volatile than the S&P 500 by 78.329%.

Ligand Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MetaVia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals pays -- of its earnings as a dividend. MetaVia pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals quarterly revenues are $42.8M, which are larger than MetaVia quarterly revenues of --. Ligand Pharmaceuticals's net income of -$31.1M is lower than MetaVia's net income of -$5.2M. Notably, Ligand Pharmaceuticals's price-to-earnings ratio is 46.13x while MetaVia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals is 11.47x versus -- for MetaVia. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -72.62% compared to Ligand Pharmaceuticals's net margin of -49.65%. Ligand Pharmaceuticals's return on equity of -0.51% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Ligand Pharmaceuticals has a consensus price target of $143.57, signalling upside risk potential of 37.69%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 60.41%. Given that NovaBay Pharmaceuticals has higher upside potential than Ligand Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Ligand Pharmaceuticals.

Ligand Pharmaceuticals has a beta of 1.099, which suggesting that the stock is 9.858% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Ligand Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals quarterly revenues are $42.8M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Ligand Pharmaceuticals's net income of -$31.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Ligand Pharmaceuticals's price-to-earnings ratio is 46.13x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals is 11.47x versus 0.14x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -72.62% compared to Ligand Pharmaceuticals's net margin of -2357.27%. Ligand Pharmaceuticals's return on equity of -0.51% beat Palatin Technologies's return on equity of --.

Ligand Pharmaceuticals has a consensus price target of $143.57, signalling upside risk potential of 37.69%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than Ligand Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Ligand Pharmaceuticals.

Ligand Pharmaceuticals has a beta of 1.099, which suggesting that the stock is 9.858% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Ligand Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals quarterly revenues are $42.8M, which are larger than Palatin Technologies quarterly revenues of $350K. Ligand Pharmaceuticals's net income of -$31.1M is lower than Palatin Technologies's net income of -$2.4M. Notably, Ligand Pharmaceuticals's price-to-earnings ratio is 46.13x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals is 11.47x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.